TKD2 Group blog

Monday Morning Coffee Newsletter, May 18, 2026

Written by Kevin Corrigan | May 18, 2026 11:00:00 AM

If you have time for an espresso

If you’re sipping a latte

If you’ve got a venti anything

  • The EV market isn’t “dead”; it’s being re-sorted around hybrids, capital discipline, and regional pragmatism. Honda’s losses and Mazda’s delay show the same thing from two angles: automakers still want electrification, but many are retreating from all-EV timelines in favor of architectures that ask less of battery supply chains and less of consumers.
    https://arstechnica.com/cars/2026/05/honda-shows-off-new-hybrids-for-america-as-it-absorbs-9-billion-ev-loss/
  • Medtech manufacturing keeps consolidating around scale, resilience, and breadth of process capability. Medical Design & Outsourcing reports Tecomet and Orchid have completed their merger, creating a larger platform across machining, additive, forging, casting, finishing, and packaging. For OEMs, that is attractive because it simplifies supplier management; for smaller specialist suppliers, it raises the bar on where they need to be truly differentiated.
    https://www.medicaldesignandoutsourcing.com/tecomet-and-orchid-complete-merger-form-global-platform/
  • Factory AI is getting more operational and less theoretical. Tech Briefs’ look at Siemens’ Eigen Engineering Agent is worth reading because it focuses on actual engineering tasks like PLC coding, HMI generation, device configuration, and standards compliance, not just generic “AI for manufacturing” claims. For automotive, battery, and regulated manufacturing teams, the interesting question is no longer whether AI will show up on the plant floor, but where it can shorten launch cycles without creating new quality or traceability problems.
    https://www.techbriefs.com/component/content/article/55175-agentic-ai-moves-from-hype-to-reality-in-automation-engineering

What it means for customers

This week’s pattern is pretty clear: customers are being pushed toward platforms and suppliers that can handle change without drama. In auto, that means hybrid-ready thinking, tighter software validation, and faster reuse of manufacturing assets; in medtech, it means regulatory discipline plus scalable, resilient production partners. For the kinds of companies TKD2 cares about, the opportunity is in helping OEMs move faster on product, process, and localization decisions while reducing launch, quality, and supply-chain risk.